NCT03175432 2026-04-15
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
52 trialsNCT05797246 2026-04-14
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT03141684 2026-04-13
Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03587311 2026-04-13
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05211323 2026-04-13
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06679985 2026-04-13
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Active not recruiting
NCT04245865 2026-04-03
Toco-CoR
Vejle Hospital
Phase 2 Active not recruiting
NCT02873962 2026-04-01
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03937830 2026-03-24
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT06040099 2026-03-19
EMERALD-Y90
AstraZeneca
Phase 2 Active not recruiting
NCT02971501 2026-03-17
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03074513 2026-03-11
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04931342 2026-03-10
BOUQUET
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04563338 2026-03-05
An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)
University Health Network, Toronto
Phase 2 Active not recruiting
NCT04721132 2026-03-05
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01946529 2026-02-23
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT02519348 2026-02-17
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
MedImmune LLC
Phase 2 Active not recruiting
NCT03896074 2026-02-09
BEAT
Fondazione Ricerca Traslazionale
Phase 2 Active not recruiting
NCT02884648 2026-02-06
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04587128 2026-02-05
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT04743661 2026-02-05
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
Pediatric Brain Tumor Consortium
Phase 2 Active not recruiting
NCT06268015 2026-02-05
BBOpCo
Duke University
Phase 2 Active not recruiting
NCT01217931 2026-01-30
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04958811 2026-01-26
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
Georgetown University
Phase 2 Active not recruiting
NCT06106308 2026-01-12
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Cardiff Oncology
Phase 2 Active not recruiting
NCT03181100 2026-01-09
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03743662 2026-01-07
Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT01871766 2025-12-17
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT06107413 2025-12-12
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
AbbVie
Phase 2 Active not recruiting
NCT05843188 2025-12-09
Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer
University Health Network, Toronto
Phase 2 Active not recruiting
NCT05781308 2025-11-18
ADAPTABLE
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Active not recruiting
NCT00977574 2025-10-31
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03526432 2025-10-24
Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
University of Oklahoma
Phase 2 Active not recruiting
NCT06784947 2025-10-02
Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer
University of Colorado, Denver
Phase 2 Active not recruiting
NCT04595266 2025-09-29
LIVERPEARL
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Active not recruiting
NCT00334815 2025-08-24
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07138885 2025-08-24
DRIVE-II
Sun Yat-sen University
Phase 2 Active not recruiting
NCT02974621 2025-08-03
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02436993 2025-07-14
Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab
University of California, Irvine
Phase 2 Active not recruiting
NCT04356729 2025-06-29
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04017455 2025-06-08
TARZAN
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT04954339 2025-05-31
DYNAMIC
Asan Medical Center
Phase 2 Active not recruiting
NCT05999812 2025-05-25
Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer
University of Texas Southwestern Medical Center
Phase 2 Active not recruiting
NCT01903330 2025-03-05
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Epitopoietic Research Corporation
Phase 2 Active not recruiting
NCT03452579 2025-02-28
Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM
Case Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT02299999 2025-01-15
SAFIR02_Breast
UNICANCER
Phase 2 Active not recruiting
NCT01531595 2024-12-12
AXOAXI
Helsinki University Central Hospital
Phase 2 Active not recruiting
NCT06667050 2024-10-31
CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer
West China Hospital
Phase 2 Active not recruiting
NCT05491811 2024-09-19
EAGLE
Sun Yat-sen University
Phase 2 Active not recruiting
NCT02308527 2024-05-14
BEACON
University of Birmingham
Phase 2 Active not recruiting